Share
     
Title
Code
Session Type
Venue
Date Time
Co-Chairs:
16:30
WEAA0301
Sting agonist as a kick and kill agent to target the HIV reservoir
Maud Mavigner, Emory University School of Medicine, United States
Abstract
Slides
16:45
WEAA0302
Different regimens of Romidepsin administration for reversion of SIV latency in a rhesus macaque model of complete virus control
Adam Kleinman, University of Pittsburgh, United States
Abstract
Slides
17:00
WEAA0303
Fingolimod treatment at ART initiation delays SIV rebound after ART interruption
Maria Pino, Yerkes National Primate Research Center, United States
Abstract
17:15
WEAA0304
Vesatolimod (GS-9620) is safe and pharmacodynamically active in HIV-infected individuals
Sharon Riddler, University of Pittsburgh School of Medicine, United States
Abstract
Slides
17:30
WEAA0305LB
Safety and virologic effect of the HIV-1 broadly neutralizing antibodies, VRC01LS or VRC07-523LS, administered to HIV-infected adults in a phase 1 clinical trial
Grace Chen, Vaccine Research Center, NIAID, NIH, United States
Abstract
AUTHOR
SUMMARY
HIGHLIGHTS
CRITICAL ASSESSMENT